These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31917969)

  • 41. Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection.
    Saha A; Dixit NM
    PLoS Comput Biol; 2020 Nov; 16(11):e1008434. PubMed ID: 33253162
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Broadly neutralizing antibodies potently inhibit cell-to-cell transmission of semen leukocyte-derived SHIV162P3.
    Suphaphiphat K; Tolazzi M; Hua S; Desjardins D; Lorin V; Dereuddre-Bosquet N; Mouquet H; Scarlatti G; Grand RL; Cavarelli M
    EBioMedicine; 2020 Jul; 57():102842. PubMed ID: 32619962
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
    Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Caregivers of children with HIV in Botswana prefer monthly IV Broadly Neutralizing Antibodies (bNAbs) to daily oral ART.
    Sakoi-Mosetlhi M; Ajibola G; Haghighat R; Batlang O; Maswabi K; Pretorius-Holme M; Powis KM; Lockman S; Makhema J; Litcherfeld M; Kuritzkes DR; Shapiro R
    PLoS One; 2024; 19(3):e0299942. PubMed ID: 38536810
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-HIV-1 Antibodies: An Update.
    Promsote W; DeMouth ME; Almasri CG; Pegu A
    BioDrugs; 2020 Apr; 34(2):121-132. PubMed ID: 32152957
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Broad and potent bispecific neutralizing antibody gene delivery using adeno-associated viral vectors for passive immunization against HIV-1.
    Li S; Qiao Y; Jiang S; Wang B; Kong W; Shan Y
    J Control Release; 2021 Oct; 338():633-643. PubMed ID: 34509584
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1.
    Lin A; Balazs AB
    Retrovirology; 2018 Oct; 15(1):66. PubMed ID: 30285769
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus.
    Ahmad M; Ahmed OM; Schnepp B; Johnson PR
    Annu Rev Virol; 2017 Sep; 4(1):491-510. PubMed ID: 28645240
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Broadly Neutralizing Antibodies for Human Immunodeficiency Virus Treatment: Broad in Theory, Narrow in Reality.
    Waters L; de Miguel-Buckley R; Poulin S; Arribas JR
    Clin Infect Dis; 2023 Mar; 76(6):1136-1141. PubMed ID: 36303321
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Editorial: Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and Prevention.
    Wagh K; van Gils MJ; Gristick H; Schommers P
    Front Immunol; 2021; 12():823576. PubMed ID: 34992615
    [No Abstract]   [Full Text] [Related]  

  • 52. Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors.
    González N; McKee K; Lynch RM; Georgiev IS; Jimenez L; Grau E; Yuste E; Kwong PD; Mascola JR; Alcamí J
    PLoS One; 2018; 13(3):e0193773. PubMed ID: 29558468
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.
    Mujib S; Liu J; Rahman AKMN; Schwartz JA; Bonner P; Yue FY; Ostrowski MA
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28592534
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
    Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 56. B-cell abnormalities and impact on antibody response in HIV infection.
    Noto A; Pantaleo G
    Curr Opin HIV AIDS; 2017 May; 12(3):203-208. PubMed ID: 28422784
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-idiotype monoclonal antibody elicits broadly neutralizing anti-gp120 antibodies in monkeys.
    Kang CY; Nara P; Chamat S; Caralli V; Chen A; Nguyen ML; Yoshiyama H; Morrow WJ; Ho DD; Köhler H
    Proc Natl Acad Sci U S A; 1992 Apr; 89(7):2546-50. PubMed ID: 1557358
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.
    Gombos RB; Kolodkin-Gal D; Eslamizar L; Owuor JO; Mazzola E; Gonzalez AM; Korioth-Schmitz B; Gelman RS; Montefiori DC; Haynes BF; Schmitz JE
    J Virol; 2015 Aug; 89(15):7813-28. PubMed ID: 25995259
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prediction of HIV-1 sensitivity to broadly neutralizing antibodies shows a trend towards resistance over time.
    Hake A; Pfeifer N
    PLoS Comput Biol; 2017 Oct; 13(10):e1005789. PubMed ID: 29065122
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody.
    Schommers P; Gruell H; Abernathy ME; Tran MK; Dingens AS; Gristick HB; Barnes CO; Schoofs T; Schlotz M; Vanshylla K; Kreer C; Weiland D; Holtick U; Scheid C; Valter MM; van Gils MJ; Sanders RW; Vehreschild JJ; Cornely OA; Lehmann C; Fätkenheuer G; Seaman MS; Bloom JD; Bjorkman PJ; Klein F
    Cell; 2020 Feb; 180(3):471-489.e22. PubMed ID: 32004464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.